drugset / Trial / NCT04983979
The ORTIZ Study: Optimising RASi Therapy With SZC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The hypothesis is that 3 months' treatment with SZC versus placebo will enable RASi (Irbesartan) maximisation in a cohort of patients with diabetic kidney disease.
Timeline
- Start
- 2022-06-17
- Primary completion
- 2023-03-16
- Completion
- 2023-05-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Zirconium Cyclosilicate | Other / unclassified | 5 g | — |
| Subject | Sodium Zirconium Cyclosilicate | Other / unclassified | 10 g | — |